Connect your AI

Glaukos GKOS Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Regeneron PharmaceuticalsREGN

$163.1M+169%

The Cooper Companies, Inc.COO

$3.9M+77.3%

ExelixisEXEL

$7.47M-35.7%

Other financials

Income statement

Revenue$150.6M+41.2%

Gross profit$117.2M+42.4%

Operating income-$19.9M+4.0%

Net income-$19.8M-9.0%

EPS (diluted)-$0.34-6.3%

Balance sheet

Cash & equivalents$104.2M-8.8%

Total debt$105.9M-1.7%

Total equity$670.9M-12.2%

Total assets$893.3M-7.5%

Cash flow

Operating cash flow-$12.5M+32.4%

CapEx$4.0M+104%

Free cash flow-$16.5M+19.4%

Valuation

Market cap$7.68B+12.3%

Enterprise value$7.68B+12.5%

P/S13.9×-3.0×

Profitability

Gross margin78.1%+2.3pp

Operating margin-36.1%+24.3pp

Net margin-34.3%+4.8pp

FCF margin-13.2%-3.9pp

Returns & leverage

Return on equity-26.4%+11.1pp

Debt / equity0.2×0.0×

Current ratio5.4×-1.1×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Glaukos's stock issuance proceeds?: Glaukos (GKOS) reported stock issuance proceeds of $19.33M in Q1 2026.
How has Glaukos's stock issuance proceeds changed year-over-year?: Glaukos's stock issuance proceeds increased by 373.5% year-over-year, from $4.08M to $19.33M.
What is the long-term trend for Glaukos's stock issuance proceeds?: Over 4 years (2021 to 2025), Glaukos's stock issuance proceeds has grown at a -15.3% compound annual growth rate (CAGR), from $26.12M to $13.45M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.